» Articles » PMID: 14758817

Uptake of BRCA1 Genetic Testing in Adult Sisters and Daughters of Known Mutation Carriers in Norway

Overview
Journal J Genet Couns
Publisher Wiley
Specialty Genetics
Date 2004 Feb 5
PMID 14758817
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

This study was undertaken to examine transmission of information to first-degree relatives of BRCA1 mutation carriers and uptake of genetic testing. The intention was to consider revision of current legislation related to privacy if information on life-saving health care was not disseminated to at-risk family members. The Norwegian Radium Hospital provides clinical genetics services for families at high risk for hereditary breast and ovarian cancer. Together with major hospitals nationwide we provide medical surveillance. Nearly all expenses are covered by the National Health insurance. Because of the high number of families with founder mutations in BRCA1, we are in a unique position to gather information about these groups. Within a consecutive series, we identified 75 BRCA1 mutation carriers and registered information transmission and uptake of genetic testing 6 months or more after the index mutation carriers had been informed about their mutation status. These 75 BRCA1 mutation carriers had 172 living first-degree relatives, aged 18 years or older (84 females, 88 males). Forty-four out of 54 (81.5%) of females over 30 had opted for genetic testing. The testing rate among all relatives was 43%. At any age, 63 % of the females underwent genetic testing compared with 24% of the males (p<0.05%). The overwhelming majority of adult females at risk opted for genetic testing. Males with daughters more frequently than males without daughters asked for testing. The findings give neither reason to reconsider legislation on privacy, nor for us to consider more aggressive methods of contacting relatives.

Citing Articles

Attitudes toward genetic testing, family planning and preimplantation genetic testing in families with a germline CDKN2A pathogenic variant.

Onnekink A, Klatte D, van Hooft J, van den Berg S, van der Zwaan S, van Doorn R Fam Cancer. 2024; 23(3):255-265.

PMID: 38822936 PMC: 11255069. DOI: 10.1007/s10689-024-00401-3.


Cascade genetic testing for hereditary cancer syndromes: a review of barriers and breakthroughs.

Levine R, Kahn R, Perez L, Brewer J, Ratner S, Li X Fam Cancer. 2024; 23(2):111-120.

PMID: 38530571 DOI: 10.1007/s10689-024-00373-4.


What happens in the long term: Uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing.

Frey M, Ahsan M, Badiner N, Lin J, Narayan P, Nitecki R Cancer. 2022; 128(24):4241-4250.

PMID: 36305018 PMC: 10041659. DOI: 10.1002/cncr.34482.


Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis.

Frey M, Ahsan M, Bergeron H, Lin J, Li X, Fowlkes R J Clin Oncol. 2022; 40(35):4129-4143.

PMID: 35960887 PMC: 9746789. DOI: 10.1200/JCO.22.00303.


The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway.

Asphaug L, Melberg H MDM Policy Pract. 2019; 4(1):2381468318821103.

PMID: 30746499 PMC: 6360477. DOI: 10.1177/2381468318821103.


References
1.
Aktan-Collan K, Mecklin J, Jarvinen H, Nystrom-Lahti M, Peltomaki P, Soderling I . Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. Int J Cancer. 2000; 89(1):44-50. View

2.
Julian-Reynier C, Sobol H, Sevilla C, Nogues C, BOURRET P . Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network. Psychooncology. 2001; 9(6):504-10. DOI: 10.1002/1099-1611(200011/12)9:6<504::aid-pon491>3.0.co;2-r. View

3.
Reichelt J, Dahl A, Heimdal K, Moller P . Uptake of genetic testing and pre-test levels of mental distress in Norwegian families with known BRCA1 mutations. Dis Markers. 1999; 15(1-3):139-43. PMC: 3850804. DOI: 10.1155/1999/581346. View

4.
Levin T, Reichelt J, Heimdal K, Moller P . [Information to families with hereditary breast and ovarian cancer]. Tidsskr Nor Laegeforen. 2002; 121(28):3292-4. View

5.
Biesecker B, Ishibe N, Hadley D, Giambarresi T, Kase R, Lerman C . Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families. Am J Med Genet. 2000; 93(4):257-63. DOI: 10.1002/1096-8628(20000814)93:4<257::aid-ajmg1>3.0.co;2-8. View